# Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC

> **NCT03674827** · PHASE1 · TERMINATED · sponsor: **Pfizer** · enrollment: 36 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer
- Triple-negative Breast Cancer

## Interventions

- **BIOLOGICAL:** PF-06936308

## Key facts

- **NCT ID:** NCT03674827
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-11-27
- **Primary completion:** 2021-09-27
- **Final completion:** 2021-09-27
- **Target enrollment:** 36 (ACTUAL)
- **Why stopped:** The study was terminated due to the review of the asset (VBIR-2) within the Sponsor's oncology portfolio; the study was not terminated because of safety concerns.
- **Last updated:** 2024-08-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03674827

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03674827, "Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03674827. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*